Sucrose-preferring gut microbes prevent host obesity by producing exopolysaccharides.

Commensal bacteria affect host health by producing various metabolites from dietary carbohydrates via bacterial glycometabolism; however, the underlying mechanism of action remains unclear. Here, we identified Streptococcus salivarius as a unique anti-obesity commensal bacterium. We found that S.

Capacitance enhancement by ion-laminated borophene-like layered materials.

Atomically flat two-dimensional networks of boron are attracting attention as post-graphene materials. An introduction of cations between the boron atomic layers can exhibit unique electronic functions that are not achieved by neutral graphene or its derivatives. In the present study, we propose a synthesis strategy for ion-laminated boron layered materials in a solution phase, which enables the preparation of analogs by changing the alkali-metal species.

Clinicopathological and immunohistochemical analysis of the risk factors of recurrence of atypical lipomatous tumor/well-differentiated liposarcoma of the extremities.

Atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDLPS) are low-grade, slow-growing, and locally aggressive tumors. We investigated clinical outcomes and recurrence factors for ALT/WDLPS of the extremities. This is retrospective study across three institutions which included patients who underwent surgery for ALT/WDLPS from 2001 to 2019.

Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib.

: Atezolizumab and bevacizumab combination therapy has been established as a standard of care for first-line treatment; however, its efficacy and safety have not been fully evaluated for patients previously treated with systemic therapy. : In this phase II trial, patients with advanced hepatocellular carcinoma previously treated with lenvatinib were enrolled to receive a dose of 1,200 mg of atezolizumab and 15 mg/kg of bevacizumab every 3 weeks. The primary endpoint was progression-free survival.